X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21338) 21338
Newsletter (140) 140
Newspaper Article (133) 133
Magazine Article (27) 27
Conference Proceeding (11) 11
Book Chapter (10) 10
Book / eBook (9) 9
Dissertation (6) 6
Publication (3) 3
Book Review (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19668) 19668
stomach neoplasms - drug therapy (11292) 11292
male (10697) 10697
female (10026) 10026
stomach neoplasms - pathology (9037) 9037
middle aged (8812) 8812
aged (8103) 8103
oncology (7666) 7666
stomach cancer (6568) 6568
gastric cancer (6041) 6041
cancer (6035) 6035
adult (5784) 5784
antineoplastic combined chemotherapy protocols - therapeutic use (4559) 4559
chemotherapy (4183) 4183
stomach neoplasms - surgery (3970) 3970
animals (3055) 3055
prognosis (3054) 3054
cell line, tumor (3050) 3050
stomach neoplasms - metabolism (2843) 2843
treatment outcome (2836) 2836
stomach neoplasms - genetics (2717) 2717
surgery (2631) 2631
adenocarcinoma - drug therapy (2551) 2551
metastasis (2506) 2506
stomach neoplasms - mortality (2390) 2390
gastroenterology & hepatology (2387) 2387
apoptosis (2255) 2255
aged, 80 and over (2234) 2234
neoplasm staging (2187) 2187
fluorouracil - administration & dosage (2177) 2177
expression (2141) 2141
tumors (2139) 2139
care and treatment (2079) 2079
mice (2050) 2050
gastrectomy (2028) 2028
cisplatin - administration & dosage (2026) 2026
research (2023) 2023
carcinoma (2014) 2014
medicine & public health (1889) 1889
antineoplastic agents - therapeutic use (1867) 1867
analysis (1749) 1749
cancer therapies (1631) 1631
survival rate (1608) 1608
health aspects (1593) 1593
drug combinations (1592) 1592
stomach neoplasms - therapy (1584) 1584
adenocarcinoma (1548) 1548
combined modality therapy (1548) 1548
cisplatin (1539) 1539
retrospective studies (1530) 1530
adenocarcinoma - pathology (1512) 1512
drug administration schedule (1454) 1454
tegafur - administration & dosage (1447) 1447
proteins (1425) 1425
gene expression (1401) 1401
medical prognosis (1383) 1383
survival (1376) 1376
helicobacter pylori (1346) 1346
therapy (1346) 1346
chemotherapy, adjuvant (1344) 1344
stomach (1329) 1329
apoptosis - drug effects (1297) 1297
mice, nude (1221) 1221
antineoplastic combined chemotherapy protocols - adverse effects (1215) 1215
pharmacology & pharmacy (1192) 1192
follow-up studies (1172) 1172
lymphatic metastasis (1157) 1157
stomach neoplasms - diagnosis (1154) 1154
immunohistochemistry (1147) 1147
risk factors (1138) 1138
antineoplastic agents - pharmacology (1117) 1117
fluorouracil (1108) 1108
helicobacter infections - drug therapy (1106) 1106
survival analysis (1104) 1104
cell proliferation - drug effects (1087) 1087
5-fluorouracil (1084) 1084
development and progression (1080) 1080
genetic aspects (1077) 1077
gene expression regulation, neoplastic (1072) 1072
patients (1064) 1064
oxonic acid - administration & dosage (1060) 1060
studies (1040) 1040
gastroenterology (1023) 1023
cancer research (1010) 1010
drug therapy (999) 999
time factors (985) 985
disease-free survival (959) 959
adenocarcinoma - surgery (952) 952
medicine (936) 936
liver neoplasms - secondary (935) 935
kinases (934) 934
research article (915) 915
antineoplastic combined chemotherapy protocols - administration & dosage (906) 906
breast-cancer (880) 880
stomach neoplasms - microbiology (878) 878
helicobacter infections - complications (873) 873
cell proliferation (867) 867
surgical oncology (860) 860
stomach neoplasms - complications (850) 850
pathology (847) 847
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18516) 18516
Japanese (2971) 2971
Chinese (447) 447
German (288) 288
Russian (241) 241
French (189) 189
Spanish (94) 94
Italian (90) 90
Korean (49) 49
Polish (28) 28
Hungarian (24) 24
Portuguese (13) 13
Czech (12) 12
Danish (11) 11
Ukrainian (11) 11
Dutch (7) 7
Norwegian (5) 5
Romanian (5) 5
Serbian (5) 5
Swedish (5) 5
Croatian (3) 3
Bulgarian (2) 2
Lithuanian (2) 2
Turkish (2) 2
Afrikaans (1) 1
Finnish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
EMBO molecular medicine, ISSN 1757-4684, 2014, Volume 6, Issue 10, pp. 1279 - 1293
Epithelial‐mesenchymal transition (EMT) is a reversible and dynamic process hypothesized to be co‐opted by carcinoma during invasion and metastasis. Yet, there... 
drug response | microarray | gene expression signature | epithelial‐mesenchymal transition | prognosis | Drug response | Epithelial-mesenchymal transition | Prognosis | Microarray | Gene expression signature | MOLECULAR SUBTYPES | MEDICINE, RESEARCH & EXPERIMENTAL | GENE-EXPRESSION SIGNATURE | STEM-CELLS | GENOMIC ANALYSES | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | CLINICAL-RELEVANCE | MICRORNA CONTROL | CLAUDIN-LOW | epithelial-mesenchymal transition | SIGNATURE PREDICTS RESISTANCE | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Epithelial-Mesenchymal Transition - drug effects | Antineoplastic Agents - therapeutic use | Epithelial-Mesenchymal Transition - genetics | Ovarian Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Female | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Treatment Outcome | Transcriptome - drug effects | Transcriptome - genetics | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Cell Line, Tumor | Cancer patients | Chemotherapy | Patient outcomes | Stem cells | Development and progression | Drug therapy | Gene expression | Ovarian cancer | Cancer | Mesenchyme | Colorectal carcinoma | Genomes | Breast cancer | Metastasis | Kinases | Cancer therapies | Metastases | Breast carcinoma | Genotype & phenotype | Paclitaxel | Breast | Software | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | CTLA-4 | LIGAND | BLOCKADE | CLINICAL ACTIVITY | PHASE-I | PD-1 | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Female | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Programmed Cell Death 1 Receptor - metabolism | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Nivolumab | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Lungs | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 04/2012, Volume 287, Issue 16, pp. 12975 - 12984
The mitotic checkpoint gene CHFR (checkpoint with fork-head-associated (FHA) and RING finger domains) is silenced by promoter hypermethylation or mutated in... 
MICROTUBULE INHIBITORS | INSTABILITY | GENE | EPIGENETIC INACTIVATION | COLORECTAL-CANCER | DNA | BIOCHEMISTRY & MOLECULAR BIOLOGY | POLY(ADP-RIBOSE) POLYMERASE-1 | CELL-CYCLE | BETA-CATENIN | EXPRESSION | Neoplasms - metabolism | Lung Neoplasms - drug therapy | Mouth Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Stomach Neoplasms - metabolism | Lung Neoplasms - pathology | Male | Mouth Neoplasms - metabolism | Stomach Neoplasms - pathology | Breast Neoplasms | Poly-ADP-Ribose Binding Proteins | Microtubules - drug effects | Genes, Tumor Suppressor - physiology | Neoplasms, Squamous Cell - drug therapy | Tumor Suppressor Proteins - genetics | Drug Design | HEK293 Cells | Female | Ubiquitination - physiology | Neoplasms, Squamous Cell - pathology | Carcinoma, Non-Small-Cell Lung - pathology | Tumor Suppressor Proteins - metabolism | Mice, Inbred C57BL | Carcinoma, Non-Small-Cell Lung - metabolism | Microtubules - physiology | Ubiquitin-Protein Ligases - metabolism | Cell Cycle Checkpoints - physiology | Stomach Neoplasms - drug therapy | Mice, Knockout | Neoplasms - drug therapy | Poly(ADP-ribose) Polymerases - metabolism | Animals | Mouth Neoplasms - pathology | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | HeLa Cells | Poly (ADP-Ribose) Polymerase-1 | Neoplasms - pathology | Ubiquitin-Protein Ligases - genetics | M Phase Cell Cycle Checkpoints - physiology | Neoplasms, Squamous Cell - metabolism | Molecular Bases of Disease | Cancer Therapy | E3 Ubiquitin Ligase | Checkpoint Control | Cell Cycle | PARP Inhibitor | Tumor Suppressor Gene | PARP-1 | CHFR
Journal Article
Journal Article
Cell reports (Cambridge), ISSN 2211-1247, 2016, Volume 15, Issue 6, pp. 1144 - 1160
Journal Article
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2017, Volume 20, Issue 1, pp. 156 - 163
The microsatellite-instable gastric cancer subtype, because of its supposed high antigenic potential, is a promising candidate for immunotherapy. We analyzed... 
Chemotherapy | Prognosis | Medicine & Public Health | Mismatch repair | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | Microsatellite instability | Surgical Oncology | Gastric cancer | ADJUVANT CHEMOTHERAPY | EFFICACY | TUMOR MICROSATELLITE-INSTABILITY | BENEFIT | ONCOLOGY | COLORECTAL-CANCER | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | Lung Neoplasms - drug therapy | Microsatellite Instability | Follow-Up Studies | Humans | Male | Stomach Neoplasms - pathology | DNA Mismatch Repair - genetics | Cisplatin - administration & dosage | Organoplatinum Compounds - administration & dosage | Peritoneal Neoplasms - drug therapy | Fluorouracil - administration & dosage | Lung Neoplasms - secondary | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Liver Neoplasms - secondary | Peritoneal Neoplasms - immunology | Neutrophils - pathology | Peritoneal Neoplasms - secondary | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Liver Neoplasms - genetics | Biomarkers, Tumor - analysis | Liver Neoplasms - drug therapy | Liver Neoplasms - immunology | Survival Rate | Combined Modality Therapy | Stomach Neoplasms - drug therapy | Stomach Neoplasms - immunology | Lung Neoplasms - immunology | Lymphocytes - pathology | Lymphocytes, Tumor-Infiltrating - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Aged | Neoplasm Staging | Lymphocytes, Tumor-Infiltrating - immunology | Cancer patients | Care and treatment | Immune response | Patient outcomes | Immunotherapy | Metastasis | Stomach cancer | Cancer
Journal Article
The Journal of clinical investigation, ISSN 1558-8238, 2017, Volume 127, Issue 8, pp. 2930 - 2940
...) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab... 
CELL LUNG-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | MELANOMA | PEMBROLIZUMAB | LIGANDS | IMMUNOTHERAPY | SAFETY | TOLERANCE | ADAPTIVE IMMUNE RESISTANCE | EXPRESSION | Immunohistochemistry | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Tumor Microenvironment | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Interferon-gamma - metabolism | Immune System | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Skin Neoplasms - immunology | Carcinoma - immunology | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Stomach Neoplasms - drug therapy | Stomach Neoplasms - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - metabolism | Lung Neoplasms - immunology | Pilot Projects | Sequence Analysis, RNA | Biopsy | Melanoma - immunology | Melanoma - drug therapy | ROC Curve | Carcinoma, Non-Small-Cell Lung - drug therapy | PD-1 protein | Lung cancer | Clinical trials | Cytotoxicity | Biology | Lymphocytes T | Cancer therapies | Metastases | Lymphocytes | Adaptation | Antigen presentation | Squamous cell carcinoma | Cytokines | Melanoma | Inflammation | Gene expression | Immune checkpoint | PD-L1 protein | Head and neck cancer | Antitumor activity | Ligands | Interferon | Chemokines | Apoptosis | Tumors
Journal Article
British journal of cancer, ISSN 1532-1827, 2008, Volume 99, Issue 4, pp. 584 - 590
Journal Article